Learn More >

Ministry Status: Activation Status

Ontario Public Drug Programs

EO Decisions and CED Recommendations

The information below is intended only to provide the recommendations and rationale from the Committee to Evaluate Drugs (CED) and the Executive Officer decisions regarding the listing of products on the Formulary, funding of cancer drugs through the New Drug Funding Program, funding through the Exceptional Access Program, or funding through the Special Drugs Program.

For further details on what types of information is provided, please refer to the Transparency of the Drug Review Process.

Do not rely upon any of the information provided on this site for medical diagnosis or treatment. Please consult your primary health care provider about any personal health concerns. This website does not provide any medical diagnosis, symptom assessment, health counseling or medical opinion for individual users. The information contained on this site is intended for information purposes only and does not constitute medical advice for patients. For more detailed information on prescription drugs, please consult a qualified healthcare professional.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Brand Name Generic Name Date Published
A
Azilect rasagiline August 2008
C
Cipralex escitalopram October 2007
Cymbalta – diabetic peripheral neuropathic pain duloxetine April 2009
E
Elaprase idursulfase May 2008
I
Invega paliperidone December 2008
J
Januvia sitagliptin December 2010
L
Leukotriene Receptor Antagonists (Singulair, Accolate) leukotriene receptor antagonists (montelukast, zafirlukast) September 2008
R
Revatio sildenafil May 2008
Rituxan rituximab January 2008
T
Tysabri natalizumab June 2008

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation : Monday to Friday, 8:30am - 5:00pm